GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Forest Laboratories Inc (FRA:FQX) » Definitions » Pretax Margin %

Forest Laboratories (FRA:FQX) Pretax Margin % : -6.47% (As of Mar. 2014)


View and export this data going back to . Start your Free Trial

What is Forest Laboratories Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Forest Laboratories's Pre-Tax Income for the three months ended in Mar. 2014 was €-51 Mil. Forest Laboratories's Revenue for the three months ended in Mar. 2014 was €790 Mil. Therefore, Forest Laboratories's pretax margin for the quarter that ended in Mar. 2014 was -6.47%.

The historical rank and industry rank for Forest Laboratories's Pretax Margin % or its related term are showing as below:

FRA:FQX' s Pretax Margin % Range Over the Past 10 Years
Min: -13.93   Med: 26.21   Max: 39.68
Current: 2.23


FRA:FQX's Pretax Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 4.185 vs FRA:FQX: 2.23

Forest Laboratories Pretax Margin % Historical Data

The historical data trend for Forest Laboratories's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forest Laboratories Pretax Margin % Chart

Forest Laboratories Annual Data
Trend Mar05 Mar06 Mar07 Mar08 Mar09 Mar10 Mar11 Mar12 Mar13 Mar14
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.67 30.27 26.99 -1.45 2.24

Forest Laboratories Quarterly Data
Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.79 4.60 10.71 2.54 -6.47

Competitive Comparison of Forest Laboratories's Pretax Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Forest Laboratories's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forest Laboratories's Pretax Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Forest Laboratories's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Forest Laboratories's Pretax Margin % falls into.



Forest Laboratories Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Forest Laboratories's Pretax Margin for the fiscal year that ended in Mar. 2014 is calculated as

Pretax Margin=Pre-Tax Income (A: Mar. 2014 )/Revenue (A: Mar. 2014 )
=58.974/2636.708
=2.24 %

Forest Laboratories's Pretax Margin for the quarter that ended in Mar. 2014 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2014 )/Revenue (Q: Mar. 2014 )
=-51.08/789.717
=-6.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Forest Laboratories  (FRA:FQX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Forest Laboratories Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Forest Laboratories's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Forest Laboratories (FRA:FQX) Business Description

Traded in Other Exchanges
N/A
Address
Forest Laboratories, Inc. is a Delaware corporation organized in 1956. The Company develops, manufactures and sells branded forms of ethical drug products most of which require a physician's prescription. The Company's most important United States products are marketed directly, or 'detailed,' to physicians by its salesforces. It emphasizes detailing to physicians of those branded ethical drugs which have the most potential for growth and benefit to patients. The Company also develops and introduces new products, including products developed in collaboration with licensing partners. The Company's products include those developed by it and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. It actively promotes in the United States those branded products which have the most potential for growth and patient benefit, and which enable its salesforces to concentrate on groups of physicians who are high prescribers of its products. Such products include: Lexapro, its SSRI for the treatment of major depression in adults and adolescents and GAD in adults; Namenda, its NMDA antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; and Savella, its newest product, an SNRI for the management of fibromyalgia. The Company's United Kingdom and Ireland subsidiaries sell both ethical products and over-the-counter preparations. Their most important products include Sudocrem, a topical preparation for the treatment of diaper rash; Colomycin, an antibiotic used in the treatment of cystic fibrosis; Infacol, used to treat infant colic; and Exorex, used in the treatment of eczema and psoriasis. The pharmaceutical industry is subject to comprehensive government regulation which substantially increases the difficulty and cost incurred in obtaining the approval to market newly proposed drug products and maintaining the approval to market existing drugs.

Forest Laboratories (FRA:FQX) Headlines

No Headlines